Last updated: 2026-09-16 09:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
TransMedics Group, Inc. (TMDX) operates in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $89.85, with a market capitalisation of $2.98B and a P/E ratio of 20.14. Over the past 52 weeks, its price has ranged from $60.11 to $156.00. This page covers its latest market performance, valuation, price trends and company information.
$2.98B | |
$88.47 | |
$177.37 | |
$10.00 | |
$88.09 | |
6.00 | |
919.89K | |
20.14 | |
$156.00 | |
$60.11 | |
-- | |
-- |
TransMedics Group, Inc. (TMDX) is trading at $89.85 in pre-market trading as of 2026-09-16 08:32:00, up 2.00% ($1.76) from the previous close of $88.09
Pre-market trading shows how investors are pricing TMDX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, TransMedics Group, Inc. (TMDX) moved from $89.98 to $89.85, representing a decline of 0.14% ($0.13).
The stock traded between $79.23 and $90.67 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 789.70 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 31.0%
TMDX is currently trading at $89.85, placing it 31.0% of the way from its 52-week low of $60.11 to its 52-week high of $156.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
| Industry | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
| Employees | 898 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of TransMedics Group, Inc. (TMDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.